[Study of anticancer human monoclonal antibody--establishment of human monoclonal antibody to gastric cancer by human-mouse hybridoma].

A human immunoglobulin M (IgM) antibody secreting hybridoma, HMG1, has been established and studied for its reactivity against human gastric cancer cells. Lymphocytes isolated from a regional lymph node of patient with gastric adenocarcinoma were fused with mouse myeloma cells NS-1. Supernatants from the generated human-mouse hybrids were first screened for immunoglobulin production by ELISA. The identified human IgM-secreting hybridomas were expanded and subcloned for further analysis or cryopreservation. The screening for binding of antibodies to a panel of human cancer cell lines and normal fibroblast was carried out with PAP or indirect immunofluorescence stain. The selected hybridoma, HMG1 after being cloned three times, was stable in secreting IgM (about 4 micrograms/1 x 10(6) cells) for more than 9 months. Large amount of ascites was obtained by injecting this hybrid to BALB/C nude mice pretreated with anti-lymphocyte serum and pristane. The ascitic fluid contained 5-19 mg human Ig/ml. Subsequently this IgM was extracted from ascitic fluid by saturated ammonium sulphate solution. This crude extract was further purified with immuno-affinity chromatography. Both this purified ascite-IgM as well as IgM from HMG1 supernatant would react with gastric cancer cell line BGC-823 but not with human normal fibroblasts 350Q by PAP or immunofluorescence analysis. The human HMG1-IgM reacted with gastric cancer cells on paraffin embedded tissue section but did not react with normal gastric mucosa cells. HMG1-IgM had some complement dependent cytotoxicity against BGC-823. These results suggest that the establishment of anticancer human monoclonal antibodies with human-mouse hybridoma technique be feasible. There is a possibility for clinical applications of this human monoclonal antibody in the future.(ABSTRACT TRUNCATED AT 250 WORDS)